HC Wainwright Reiterates Buy Rating for BriaCell Therapeutics (NASDAQ:BCTX)

BriaCell Therapeutics (NASDAQ:BCTX)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $15.00 price objective on the stock.

BriaCell Therapeutics Stock Performance

Shares of BriaCell Therapeutics stock opened at $0.66 on Thursday. The firm has a market capitalization of $23.88 million, a PE ratio of -0.56 and a beta of 1.46. The business’s 50-day moving average price is $0.84 and its 200-day moving average price is $0.89. BriaCell Therapeutics has a 12 month low of $0.46 and a 12 month high of $5.97.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings data on Monday, October 28th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.45. As a group, analysts predict that BriaCell Therapeutics will post -1.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned about 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.